The rise of virtual business models in biopharma reflects the changing face of the pharmaceutical industry - big pharma discovering and developing its own pipeline exclusively in-house no longer exists.
Cliodhna McDonough says new regulations on the horizon for medical devices in Europe present a huge challenge to manufacturers, but could also deliver improved confidence in the consistency and effectiveness of the regulatory process.
CRISPR has the potential to transform a variety of scientific areas, but this genome editing technique is also shrouded in controversy, particularly regarding its potential use to create genetically engineered humans.
The traditional pharma industry is eyeing the rise of Digital Therapeutics as patient outcomes fast become the only metric to sweat over. Their combined effect is setting the scene for a radical transformation of the industry. Its survival as a dominant force in shaping healthcare will depend on how it responds.
Excitement around the transformative potential of AI and machine learning continues to build. Companies will need to adapt their individual offers to draw in AI specialists, but as an industry UK pharma should also continue to champion itself and the unique career advantages it holds for the best and brightest researchers.
Professor Chris Whitty, chief scientific adviser for the Department of Health and Social Care (DHSC), on the role of the NIHR and the promise of the government's second sector deal for the life sciences industry.
There are around 7,000 rare diseases for which there currently exists no authorised or satisfactory method of treatment, highlighting a vast area of unmet need, and yet the clinical development of orphan drugs is still fraught with many practical challenges.